NASDAQ$SIGA

SIGA Technologies, Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

SIGA Technologies' financial performance was mixed, with increased international sales offset by operating losses.

SIGA Technologies reported a positive trend in international sales, with approximately $3 million of oral TPOXX® delivered to the Public Health Agency of Canada in the first quarter. Total revenues increased to $4.8 million compared to $2.6 million in the same period last year. The company's operating loss was $(2.0) million, and its net loss was $(0.8) million, with a diluted loss per share of $(0.02).

  • Total revenues increased to $4.8 million compared to $2.6 million year-over-year.
  • Approximately $3 million of oral TPOXX® was delivered to the Public Health Agency of Canada in Q1.
  • Operating loss was $(2.0) million, an improvement from $(4.0) million in the prior year.
  • The company filed a new drug application with the FDA for the intravenous formulation of TPOXX.

Headline financials

Total Revenue

$4.81M

Previous: $2.62M+83.7%
EPS (adj)

-$0.02

Previous: -$0.05+60.0%
Capital Expenditures

-$13.7K

Previous: -$15.5K+11.5%
Free Cash Flow

-$826K

Previous: -$8.91M+90.7%
Net Income

-$812K

Previous: -$8.9M+90.9%
Operating Income

-$1.99M

Previous: -$4M+50.2%
Gross Profit

$4.56M

Previous: $2.51M+81.7%
Cash & Equivalents

$107M

Previous: $77.4M+37.7%
Total Assets

$139M

Previous: $119M+17.0%
Stock-Based Comp

$246K

Previous: $259K-4.9%

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$4.81M

Q1 2021+83.7%vs Q1 2020
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Revenue by segment

SIGA Technologies · $4.81M total across 2 segments · Q1 2021

  • Product Sales
    $3.52M+3017.8%
  • R&D Revenues
    $1.29M-48.5%

Forward guidance

SIGA Technologies anticipates BARDA sales to be concentrated in the second half of 2021, while international sales are expected to be concentrated in the first half of 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro